(f) and (g) To the extent information is available, there is no indigenous production of medicines based on Cyclosporin required for organ transplantation.

(h) and (i) To the extent information is available, the imported raw material required for manufacture of drug for AIDS and imported finished medicine on this drug attracts custom duty. The proposal for custom duty exemption on intermediates for manufacturing of drug for AIDS was received and the same was recommended to Ministry of Finance for their appropriate action.

Cost study by BICP

3095. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to refer to answer to Unstarred Question 645 given in the Rajya Sabha on the 5th September, 1991 and state:

(a) how much time was taken by BICP to conduct cost study after Government sent directions;

(b) when was the price of vovern tablets which is based on Diclofenac Sodium fixed during the year 1990-91 and what was its earlier and revised price;

(c) who are the producers of Dicofenac Sodium and what was the production of each during the last three years, year-wise;

(d) when did BICP conduct cost-cum-technical study of this drug and when did Government receive recommendations;

(e) what was the price recommended and what prices was notified;

(f) what is the present price per kg;

(g) what are the names of drugs for which Government have still to receive recommendations of cost-cum-technical study; and

(h) when did Government ask and what is the reasons for delay in each case?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) The time taken by BICP to conduct cost study after Government send directions depends on the number of units involved, response to the questionnaires issued by BICP and so many other connected factors.

(b) The price of Voveran Tablets based on Diclofenac Sodium was Rs. 12.07 for 10's strip as per MIMS in April, 1990 and the price of the same was revised in November, 1990 to Rs. 4.90.

(c) To the extent information is available, M/s. Hindustan Ciba Geigy and M/s. Unique Chemicals are the producers of this drug. The details of production have to be collected from the producers and will be placed on the Table of the House.

(d) to (f) The BICP conducted the cost-cum-technical study of Diclofenac Sodium in 1991 and forwarded its recommendations in September, 1991 which are under examination in this Ministry and a view on this would be taken shortly. At present there is no notified price for this bulk drug. The DPRC Sub Committee has been adopting a price of Rs. 5027.55 per kg. as an interim price of bulk drug for regulating the prices of formulations based on this drug.

(g) and (h) The conducting of cost-cum-technical study by the BICP and sending their recommendations to this Ministry is an on-going process.

Total number of Multinational drug Companies

3096. SHRI M. A. BABY: Will the PRIME MINISTER be pleased to state:

(a) what is the Total number of Multinational drug Companies operating in India and what is the foreign equity in each case:

(b) what is the profit of each and the capital employed in each of these drug Companies:

(c) what are the names of drugs for which permission to manufacture has been granted to each of them during the last

three years year-wise and how many permission have been implemented by each of these drug Companies.

(d) what are the names of drugs being imported by these Companies for which each of them has been granted permission to manufacture; and

(e) what are the names of drugs of each Company which are exempted from price control and what is the present price of each per unit?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) The required details to the extent available are given in statement-I (*See* below).

(c) The details to the extent available are given in statement-II

(d) Company-wise imports of drugs are not monitored.

(e) The required details are quite voluminous. The time and effort required for collection of these would not be commensurate with the results likely to be achieved.

Statement

Sl. No.	Name of the Company	Foreign Equity Percentage (As on 30-4-90)	Profit before Tax (Rs in lakhs)	
			Year	Amount
1	2	3	4	5
1.	M/s. Bayer India Ltd.	51.01		
2.	M/s. Johnson & Johnson Ltd.	75		
3.	M/s. ICI Ltd.	52.94		
4.	M/s. Sandoz (I) Ltd.	50.94	1990 (Jan to Dec.)	943
5.	M/s. Wyeth Labs.	74		
6	M/s. Roche Products	74		
7	M/s. Anglo French	40		
8.	M/s. Cater Wallace	40		
9.	M/s. C.E. Fulford	40		
10.	M/s. Abbott Labs.	40		
11.	M/s. Eskayef Ltd.	40		
12.	M/s. Geoffrey Manners	40	1989-90	516
13.	M/s. Parke Davis	40		
14.	M/s. Warner Hindustan	40		
15.	M/s. Hindustan Ciba-Geigy of India Ltd.	40	1989-90	2602
16.	M/s. Infar India Ltd.	40		
17.	M/s. Rhone Poulene India Ltd.	40		
18.	M/s. Glaxo India Ltd.	40	1989-90	1522
19.	M/s. Merind Ltd.	40	1989-90	107
20.	M/s. Burroughs Wellcome (I) Ltd.	40	1990-91	443

1	2	3	4	5
21.	M/s. Procter & Gamble (I) Ltd.	40		
22.	M/s. Cynamid India Ltd.	40		
23.	M/s. Pfizer Ltd.	40		
24.	M/s. Boots Co. (I) Ltd.	40		
25.	M/s. E. Merck (I) Ltd.	40	1990 (Jan. to Dec.)	230
26.	M/s. Hoechst	40	1989-90	1082 (Includes payment of Rs. 12 lakhs to DPEA)

Statement

Sl. No.	Name of the Company	Items of manufaoture for which approval given.
1	2	3
		Year : 1989
1.	M/s. Sandoz (I) Ltd.	Bromocribtine
2.	M/s. German Remedies	Dipyridomole
3.	M/s. Glaxo (I) Ltd.	Betamethasone
		Beclomethasone
		Clobetasone
		Ethisterone
		Progesterone
		Ethinyl Cestrodial
		Testosterone Propionate
		Dimethisterone
		Magestrol Acetate
4.	M/s. Reckit & Colemen	Triclosan
5.	M/s. Hoechst (I) Ltd.	Fenbendazole
		Tonophosphan Substance
		Berenil Substance
		Baralgan Ketone
6.	M/s. Merind Ltd.	Amiloride Hcl.
		Amitriplytine Hcl.
		Norfloxacin

1	2	3
7.	M/s. Hindustan Ciba-Geigy (I) Ltd.	Pyrazinamide
8.	M/s. May & Baker (I) Ltd.	Metronidazole
9.	M/s. Eskayef Ltd.	Fenbendazole
		Amoxycillin Trihydrate
		5-Amino Salicylic Acid
		Norfloxacin
10.	M/s. Anglo Brench	Mebendazole
		Depsone
		Atenolol
	Year : 1990	
1.	M/s. E. Merck (I) Ltd.	Guaiazulene Crystal
2.	M/s. Astra-IDL Ltd.	Prostaglandin
		Norfloxacin/Diclofenac Sodium
3.	M/s. Reckit & Colemen	3,5 Dibenzylozy Acetophenone
4.	M/s. Hoechst (I) Ltd.	Glybenclamide
5.	M/s. Pfizer Ltd.	Chlorpropamide, Tinadazole
6.	M/s. Hindustan Ciba-Geigy (i) Ltd.	Dihydrollazine
7.	M/s. Sandoz (I) Ltd.	Ketotifon
8.	M/s. E. Merck Ltd.	Guiazulene Crystal
		Collidol Bismuth
9.	M/s. Boehringer Knoll	Ciprofloxacin
10.	M/s. Uni-Sankyo	Pyrazinanidine
11.	M/s. Eskayef	Cloxacillin
12.	M/s. Wockhardt	Povidone Iodine
		Nefopam/Benzalhonium Chloride
13.	M/s. Abbott Labs.	Erythromycin
	Year : 1991	
1.	M/s. Hoechst (I) Ltd.	Roxatidine Acetate Hydrochloride
2.	M/s. Pfizer Ltd.	Salinomycin
3.	M/s. Boehringer Knoll	Chloramphenicol
4.	M/s. Cynamid	Loxapin
5.	M/s. Abbott Labs.	Erythromycin
6.	M/s. Duphar Interfran	Isoxsuprine Hcl.